Central and eastern Europe: market opportunities or a regulatory headache?
This article was originally published in Clinica
Is now a good time for EU medical device manufacturers to consider entering the markets of central and eastern Europe? Or would it be advisable to wait until these countries become members of the European Union and have implemented the EU's medical device directives? Amanda Maxwell reports
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.